WT1 and myelodysplastic syndrome: WT1-mRNA is used as a specific and sensitive diagnostic and prognostic marker of AML and MDS, especially in the absence of specific molecular signature, as expression levels can mirror disease progression and identify MDS patients with poorer prognosis (Giudice V et al., 2021).